HTB homepage • Conference reports • Articles by subject • Subscribe June 2015 Contents Editorial May/June 2015: Volume 16 Number 5/6 In memory Remembering Professor Martin Fisher Treatment alerts Early START results recommend ART for all study participants: starting HIV meds when the CD4 count is above 500 reduces AIDS-related events Conference reports 21st Annual BHIVA Conference, 21-24 April 2015, Brighton BHIVA pregnancy audit 2013 to 2014 Transmitted drug resistance in HIV positive pregnant women Primary HIV infection and early use of ART Rectal STIs and viral load in HIV positive men on and off ART Impact of age and HIV on use of non-HIV meds: early results on health care use in the POPPY study Other short reports from BHIVA: 2015 Conference on Retroviruses and Opportunistic Infections (CROI), 23-26 February 2015, Seattle Elvitegravir in children and adolescents PK of ARVs in pregnancy: rilpivirine, etravirine and raltegravir HIV and cardiovascular disease 5th International Workshop on HIV & Women , 21-22 February 2015, Seattle, Washington Pharmacokinetics in pregnancy: darunavir/r and etravirine Low prolactin and high 20alpha-HSD might contribute to ART-associated progesterone deficits in pregnancy Pregnancy rates among women using ART and hormonal contraceptives in Kenya Adolescents at increased risk of vertical transmission and poor pregnancy outcome in South Africa Gender difference in virological response to ART Antiretrovirals Generic dolutegravir submitted to FDA for tentative approval EMA approves coformulated atazanavir/cobicistat Dual F/TAF formulation under evaluation by EMA Treatment access Lopinavir/ritonavir pellets tentatively approved by the FDA Sofosbuvir access: new patent challenges to sofosbuvir Guidelines US guidelines shift to integrase-based combinations for first-line treatment (2015): Atripla relegated due to side effects EACS guidelines (2015): translations in 11 languages now available online Recommendations for management of bone health in people living with HIV TB coinfection New clinical trial for extensively drug resistant TB (XDR-TB) MSF report and call to action: Promising new TB drugs are not reaching patients HIV prevention and transmission Methmephangee – ChemSex vs recreational drug use: a proposed definition for health workers Basic science and immunology Timing of very early ART to limit early HIV-related mucosal dysfunction Broad CD8 T cell responses are required to overcome dominance of CTL escape in the latent HIV reservoir Broadly neutralising antibody suppresses HIV in clinical trial Other news WHO statement for public disclosure of clinical trial results PDFs May/June 2015: Volume 16 Number 5/6 HTB homepage • Conference reports • Articles by subject • Subscribe
